Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care.
METHODS: All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Cancer Registry. Patients diagnosed and/or treated in 2020 were compared to 2017-2019. Monthly incidence was calculated. Patient, tumor and treatment characteristics were analyzed and compared using Chi-squared tests. Survival data was analyzed using Kaplan-Meier and Log-rank tests.
RESULTS: In total, 11019 patients were assessed. The incidence in quarter (Q)2 of 2020 was comparable with that in Q2 of 2017-2019 (p = 0.804). However, the incidence increased in Q4 of 2020 (p = 0.031), mainly due to a higher incidence of metastatic disease (p = 0.010). Baseline characteristics, surgical resection (15% vs 16%; p = 0.466) and palliative systemic therapy rates (23% vs 24%; p = 0.183) were comparable. In 2020, more surgically treated patients received (neo)adjuvant treatment compared to 2017-2019 (73% vs 67%; p = 0.041). Median overall survival was comparable (3.8 vs 3.8 months; p = 0.065).
CONCLUSION: This nationwide study found a minor impact of the COVID-19 pandemic on pancreatic cancer care and outcome. The Dutch health care system was apparently able to maintain essential care for patients with pancreatic cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
HPB : the official journal of the International Hepato Pancreato Biliary Association - 25(2023), 10 vom: 19. Okt., Seite 1195-1202 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 29.09.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hpb.2023.04.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357390881 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357390881 | ||
| 003 | DE-627 | ||
| 005 | 20231227131301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hpb.2023.04.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM357390881 | ||
| 035 | |a (NLM)37236831 | ||
| 035 | |a (PII)S1365-182X(23)00134-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Graus, Merlijn U J E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care | ||
| 520 | |a METHODS: All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Cancer Registry. Patients diagnosed and/or treated in 2020 were compared to 2017-2019. Monthly incidence was calculated. Patient, tumor and treatment characteristics were analyzed and compared using Chi-squared tests. Survival data was analyzed using Kaplan-Meier and Log-rank tests | ||
| 520 | |a RESULTS: In total, 11019 patients were assessed. The incidence in quarter (Q)2 of 2020 was comparable with that in Q2 of 2017-2019 (p = 0.804). However, the incidence increased in Q4 of 2020 (p = 0.031), mainly due to a higher incidence of metastatic disease (p = 0.010). Baseline characteristics, surgical resection (15% vs 16%; p = 0.466) and palliative systemic therapy rates (23% vs 24%; p = 0.183) were comparable. In 2020, more surgically treated patients received (neo)adjuvant treatment compared to 2017-2019 (73% vs 67%; p = 0.041). Median overall survival was comparable (3.8 vs 3.8 months; p = 0.065) | ||
| 520 | |a CONCLUSION: This nationwide study found a minor impact of the COVID-19 pandemic on pancreatic cancer care and outcome. The Dutch health care system was apparently able to maintain essential care for patients with pancreatic cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a de Hingh, Ignace H J T |e verfasserin |4 aut | |
| 700 | 1 | |a Besselink, Marc G |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Marco J |e verfasserin |4 aut | |
| 700 | 1 | |a Wilmink, Johanna W |e verfasserin |4 aut | |
| 700 | 1 | |a de Meijer, Vincent E |e verfasserin |4 aut | |
| 700 | 1 | |a van Velthuysen, Marie-Louise F |e verfasserin |4 aut | |
| 700 | 1 | |a Valkenburg-van Iersel, Liselot B J |e verfasserin |4 aut | |
| 700 | 1 | |a van der Geest, Lydia G M |e verfasserin |4 aut | |
| 700 | 1 | |a de Vos-Geelen, Judith |e verfasserin |4 aut | |
| 700 | 0 | |a Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium |e verfasserin |4 aut | |
| 700 | 0 | |a Dutch Nationwide Pathology Databank (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief, PALGA) |e verfasserin |4 aut | |
| 700 | 0 | |a SONCOS (Dutch Multidisciplinary Oncology Foundation) |e verfasserin |4 aut | |
| 700 | 1 | |a Siesling, S |e investigator |4 oth | |
| 700 | 1 | |a van Hoeve, J C |e investigator |4 oth | |
| 700 | 1 | |a Merkx, M A W |e investigator |4 oth | |
| 700 | 1 | |a de Wit, N J |e investigator |4 oth | |
| 700 | 1 | |a Helsper, C W |e investigator |4 oth | |
| 700 | 1 | |a Dingemans, I |e investigator |4 oth | |
| 700 | 1 | |a Nagtegaal, I D |e investigator |4 oth | |
| 700 | 1 | |a van der Schaaf, M |e investigator |4 oth | |
| 700 | 1 | |a van Gils, C H |e investigator |4 oth | |
| 700 | 1 | |a van Weert, H C P M |e investigator |4 oth | |
| 700 | 1 | |a Verheij, M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t HPB : the official journal of the International Hepato Pancreato Biliary Association |d 2001 |g 25(2023), 10 vom: 19. Okt., Seite 1195-1202 |w (DE-627)NLM178147761 |x 1477-2574 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g day:19 |g month:10 |g pages:1195-1202 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hpb.2023.04.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 10 |b 19 |c 10 |h 1195-1202 | ||